


Bispecific Antibody & Cancer

Patent Landscape Analysis

January 2025



SAMPLE

TABLE OF CONTENTS

<u>INTRODUCTION</u>	<u>5</u>	<u>PATENT SEGMENTATION</u>	<u>60</u>
<ul style="list-style-type: none">- BsAb for cancer therapy- Scope of the report- Reading guide- Main patent assignees		<ul style="list-style-type: none">- Definition- Main assignees by technology- CD3- Immune Checkpoint- Tumor Antigen	
<u>EXECUTIVE SUMMARY</u>	<u>11</u>	<u>IP PROFILE OF KEY PLAYERS</u>	<u>71</u>
<u>PATENT LANDSCAPE OVERVIEW</u>	<u>16</u>	Overview, key patents & clinical trials of:	
<ul style="list-style-type: none">- Time evolution of patent publications- Ranking of most prolific patent applicants- Current legal status of the main players- Patent legal status of the corpus- Mapping of main current IP holders- Time evolution of main patent assignees		<ul style="list-style-type: none">- Amgen- Genentech- Roche- GenMab- Janssen- Regeneron- Xencor	
<u>NEWCOMERS</u>	<u>24</u>	<u>METHODOLOGY</u>	<u>115</u>
<ul style="list-style-type: none">- Startup companies- Established companies		<ul style="list-style-type: none">- Patent search, selection and analysis- Search strategy- Terminologies for patent analysis- Strength and blocking potential	
<u>COLLABORATIONS</u>	<u>32</u>	<u>KNOWMADE PRESENTATION</u>	<u>122</u>
<u>IP POSITION OF MAIN APPLICANTS</u>	<u>46</u>	<u>CONTACT</u>	<u>126</u>
<ul style="list-style-type: none">- IP leadership of patent applicants- IP prior art blocking potential of patent applicants- Key patents- Strength index of patent portfolios			
<u>MAIN EP PATENT OPPOSITIONS</u>	<u>54</u>		

THE AUTHORS



PhD Fabienne Massa

Fabienne works for Knowmade in the field of Biotechnology and Life Sciences. She holds a PhD in Molecular and Cellular Biology from the IPMC (Sophia Antipolis, France). She also holds a Master of Business Management from IAE (Nice, France) and she previously worked in the pharmaceutical industry.

Contact: fabienne.massa@knowmade.fr



PhD Brice Sagot

CTO and co-founder of KnowMade. He leads the Biotechnology and Life Sciences department. He holds a PhD in Molecular Biology from the University of Nice Sophia-Antipolis (France).

Contact: brice.sagot@knowmade.fr

Specialized in analysis of patents and scientific information, Knowmade provides Technology Intelligence and IP strategy consulting services. The company is supporting R&D organizations, industrial companies and investors in their business development by offering them a deep understanding of the technology trends and their IP environment. Knowmade operates in the following industrial sectors: Microelectronics, Compound Semiconductors, Power Electronics, RF & Microwave Devices, MEMS Sensors & Actuators, LED/OLED, Imaging & Display, Photonics, Battery, Manufacturing & Advanced Packaging, Micro & Nanotechnology, Biotechnology, Cellular & Molecular Biology, Microbiology, Dermatology, Pharmacology, Oncology, Immunology, Medical Devices & Medical Imaging, Agri-Food & Environment. Knowmade performs prior art search, patent landscape analysis, scientific literature analysis, patent valuation and freedom-to-operate analysis. In parallel, the company proposes litigation/licensing support, technology scouting and IP watch service. Knowmade's analysts combine their technical and patent expertise by using powerful analytics tools and proprietary methodologies to deliver relevant patent analyses and scientific reviews.

We Know Technology, We Know Patents

INTRODUCTION

Scope of the report

- This report provides a detailed picture of the patent landscape for **Bispecific Antibody & Cancer**.
- This report covers **patents published worldwide up to August 2024**.
- We have selected and analyzed about **+2890 patent families** relevant to the scope of this report.

You want a deeper analysis on technologies or companies

Contact us for a custom report



Included in the report

- ✓ All cancer: hematological cancers (e.g., leukemia, lymphoma), solid cancers (e.g., prostate cancer, melanoma) and virus-induced cancers (e.g., HPV, EBV)
- ✓ All antibody formats: bispecific, trispecific, tandem, diabody, crossMab, etc.
- ✓ All antigens / epitopes recognition: tumor antigens (e.g., PSMA, BRCA), immune checkpoints (e.g., PD-1, CTLA-4) and immune cell receptors (e.g., CD3, CD28)

Not included in the report

- X Other therapeutic applications: virus or bacteria infection, diabetes, cardiovascular pathology, etc.
- X Drug coupled to an antibody: antibody drug conjugate
- X Radio-molecule coupled to an antibody: radiopharmaceutical
- X Bispecific chimeric antigen receptor

INTRODUCTION

Key features of the report

- **Excel database** comprising all analyzed patents of the report is provided.
- This **patent database** allows multi-criteria searches, including:
 - Patent publication number
 - Hyperlinks to the original documents
 - Priority date
 - Title
 - Abstract
 - Patent assignees
 - Technical segmentation
 - Legal status for each member of the patent family.
- The findings, interpretations and conclusions expressed in this report are entirely those of Knowmade and may not constitute or imply endorsement by a decision-making body such as a court of law or a patent office. Any assessment of the effect or scope of pending applications or granted patents reflects our own views and these are not necessarily those of a Patent Attorney. Should confirmation of our assessment in this respect be required, we recommend that you seek the advice of a national Patent Attorney.



Patent Landscape Overview

Identify main EP oppositions, collaborations and newcomers

SAMPLE

MAIN EP PATENT OPPOSITIONS

Main oppositions on EP patents (1/5)

This table shows main [oppositions](#) filed against European patents. For each opposed patent, application date, assignee, opponent, opposition year and results are presented.

Assignee	Opposed Patent	Application filing date	Opponent	Opposition year	Title	Result
ASTAR	EP3428181	2016-06-05	Tensaris	2021	IG202a/constant gamma chain antibodies	Ongoing




IP COLLABORATIONS

Main IP collaborations (1/12)

Co-assignees	Organization type	Representative members of patent families	Link	Earliest publication years	Title
AMBIT (led by FRODOUARD SAS)	INDUSTRIAL	EP1811			
AMBI	INDUSTRIAL	EP1680			
AMBI	INDUSTRIAL	EP1681			
AMBI	INDUSTRIAL	EP1682			
AMBI	INDUSTRIAL	EP1683			
AMBI	INDUSTRIAL	EP1684			
AMBI	INDUSTRIAL	EP1685			
AMBI	INDUSTRIAL	EP1686			
AMBI	INDUSTRIAL	EP1687			
AMBI	INDUSTRIAL	EP1688			
AMBI	INDUSTRIAL	EP1689			
AMBI	INDUSTRIAL	EP1690			
AMBI	INDUSTRIAL	EP1691			
AMBI	INDUSTRIAL	EP1692			
AMBI	INDUSTRIAL	EP1693			
AMBI	INDUSTRIAL	EP1694			
AMBI	INDUSTRIAL	EP1695			
AMBI	INDUSTRIAL	EP1696			
AMBI	INDUSTRIAL	EP1697			
AMBI	INDUSTRIAL	EP1698			
AMBI	INDUSTRIAL	EP1699			
AMBI	INDUSTRIAL	EP1700			
AMBI	INDUSTRIAL	EP1701			
AMBI	INDUSTRIAL	EP1702			
AMBI	INDUSTRIAL	EP1703			
AMBI	INDUSTRIAL	EP1704			
AMBI	INDUSTRIAL	EP1705			
AMBI	INDUSTRIAL	EP1706			
AMBI	INDUSTRIAL	EP1707			
AMBI	INDUSTRIAL	EP1708			
AMBI	INDUSTRIAL	EP1709			
AMBI	INDUSTRIAL	EP1710			
AMBI	INDUSTRIAL	EP1711			
AMBI	INDUSTRIAL	EP1712			
AMBI	INDUSTRIAL	EP1713			
AMBI	INDUSTRIAL	EP1714			
AMBI	INDUSTRIAL	EP1715			
AMBI	INDUSTRIAL	EP1716			
AMBI	INDUSTRIAL	EP1717			
AMBI	INDUSTRIAL	EP1718			
AMBI	INDUSTRIAL	EP1719			
AMBI	INDUSTRIAL	EP1720			
AMBI	INDUSTRIAL	EP1721			
AMBI	INDUSTRIAL	EP1722			
AMBI	INDUSTRIAL	EP1723			
AMBI	INDUSTRIAL	EP1724			
AMBI	INDUSTRIAL	EP1725			
AMBI	INDUSTRIAL	EP1726			
AMBI	INDUSTRIAL	EP1727			
AMBI	INDUSTRIAL	EP1728			
AMBI	INDUSTRIAL	EP1729			
AMBI	INDUSTRIAL	EP1730			
AMBI	INDUSTRIAL	EP1731			
AMBI	INDUSTRIAL	EP1732			
AMBI	INDUSTRIAL	EP1733			
AMBI	INDUSTRIAL	EP1734			
AMBI	INDUSTRIAL	EP1735			
AMBI	INDUSTRIAL	EP1736			
AMBI	INDUSTRIAL	EP1737			
AMBI	INDUSTRIAL	EP1738			
AMBI	INDUSTRIAL	EP1739			
AMBI	INDUSTRIAL	EP1740			
AMBI	INDUSTRIAL	EP1741			
AMBI	INDUSTRIAL	EP1742			
AMBI	INDUSTRIAL	EP1743			
AMBI	INDUSTRIAL	EP1744			
AMBI	INDUSTRIAL	EP1745			
AMBI	INDUSTRIAL	EP1746			
AMBI	INDUSTRIAL	EP1747			
AMBI	INDUSTRIAL	EP1748			
AMBI	INDUSTRIAL	EP1749			
AMBI	INDUSTRIAL	EP1750			
AMBI	INDUSTRIAL	EP1751			
AMBI	INDUSTRIAL	EP1752			
AMBI	INDUSTRIAL	EP1753			
AMBI	INDUSTRIAL	EP1754			
AMBI	INDUSTRIAL	EP1755			
AMBI	INDUSTRIAL	EP1756			
AMBI	INDUSTRIAL	EP1757			
AMBI	INDUSTRIAL	EP1758			
AMBI	INDUSTRIAL	EP1759			
AMBI	INDUSTRIAL	EP1760			
AMBI	INDUSTRIAL	EP1761			
AMBI	INDUSTRIAL	EP1762			
AMBI	INDUSTRIAL	EP1763			
AMBI	INDUSTRIAL	EP1764			
AMBI	INDUSTRIAL	EP1765			
AMBI	INDUSTRIAL	EP1766			
AMBI	INDUSTRIAL	EP1767			
AMBI	INDUSTRIAL	EP1768			
AMBI	INDUSTRIAL	EP1769			
AMBI	INDUSTRIAL	EP1770			
AMBI	INDUSTRIAL	EP1771			
AMBI	INDUSTRIAL	EP1772			
AMBI	INDUSTRIAL	EP1773			
AMBI	INDUSTRIAL	EP1774			
AMBI	INDUSTRIAL	EP1775			
AMBI	INDUSTRIAL	EP1776			
AMBI	INDUSTRIAL	EP1777			
AMBI	INDUSTRIAL	EP1778			
AMBI	INDUSTRIAL	EP1779			
AMBI	INDUSTRIAL	EP1780			
AMBI	INDUSTRIAL	EP1781			
AMBI	INDUSTRIAL	EP1782			
AMBI	INDUSTRIAL	EP1783			
AMBI	INDUSTRIAL	EP1784			
AMBI	INDUSTRIAL	EP1785			
AMBI	INDUSTRIAL	EP1786			
AMBI	INDUSTRIAL	EP1787			
AMBI	INDUSTRIAL	EP1788			
AMBI	INDUSTRIAL	EP1789			
AMBI	INDUSTRIAL	EP1790			
AMBI	INDUSTRIAL	EP1791			
AMBI	INDUSTRIAL	EP1792			
AMBI	INDUSTRIAL	EP1793			
AMBI	INDUSTRIAL	EP1794			
AMBI	INDUSTRIAL	EP1795			
AMBI	INDUSTRIAL	EP1796			
AMBI	INDUSTRIAL	EP1797			
AMBI	INDUSTRIAL	EP1798			
AMBI	INDUSTRIAL	EP1799			
AMBI	INDUSTRIAL	EP1800			

IP NEWCOMERS

Startup companies (2/3)

Assignee	Company information	Company size	Patent family	Main relevant selected patent family
	NONA BIOSCIENCES (a wholly-owned subsidiary of eMed Holding) is a global biotechnology US company, founded in 2003, which provides a solution from "Tobacco to IPD", ranging from target validation and Ab discovery through preclinical research. The integrated Ab and Ab discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to Ab lead generation and engineering, developmental assessment and pharmaceutical evaluation, leveraging advantages of Harbour MAb [®] platform and the experienced therapeutic Ab discovery team.	~ 50	1	CD3-targeting antibody and use thereof (EP3100476/101000) - 2024 The patent family describes CD3-targeting antibodies and bispecific antibodies targeting both CD3 and tumor-associated antigens. Anti-CD3 Ab comprises a B2B4 fragment (single variable domain 1 st of heavy chain Ab), anti-B2B4 antibody, anti-CD3 antibody and use thereof (EP3100476 - 2024) The invention relates a B2B4 targeting antibody that binds human B2B4 and synergizes mouse B2B4 and does not cross-react with other B2 family members. It exhibits good anti-tumor activity, T-cell activation in vivo and in-vitro experiments. It is also described a bispecific antibody targeting B2B4 and CD3, which has a longer half-life, retains good stability and hydrophilicity, and reduces toxicity while ensuring efficacy. 4-1BB binding protein and application thereof (EP4100119 - 2025) The 4-1BB-binding protein of this invention is a full human antibody having the binding activity to human 4-1BB and synergizes monkey 4-1BB. Some 4-1BB-binding proteins are only half the size of conventional IgG antibodies, they can be well used for bispecific antibodies.
	Centessa Pharmaceuticals is a US clinical stage pharmaceutical company, founded in 2021, with a R&D that aims to discover and develop medicines with indications in rare diseases and immunology.	~ 50	1	Activatable bispecific anti-CD47 and anti-PD-L2 proteins and use thereof (EP3000000/101110) - 2025 Provided are proteins that specifically bind PD-L2 and exhibit activatable specific CD8 binding in cancer tissues. Activatable bispecific anti-CD47 and anti-PD-L2 proteins and use thereof (EP3000000/101110) - 2025 Provided are proteins that specifically bind PD-L1 and exhibit activatable specific CD47 binding in cancer tissues. Activatable bispecific antibodies comprising a linker ... (EP3000000/101110) - 2025 A protein comprising a 2 nd moiety capable of binding to a molecule expressed in a diseased tissue; a peptide linker cleavable by a protease expressed in a diseased tissue; and a 2 nd moiety capable of binding to a molecule expressed in the diseased tissue. The binding of the 2 nd moiety is inhibited when the peptide linker is uncleaved.
	EvolveImmune Therapeutics is an American company founded in 2020. It's proprietary immunology platform delivers both sustained immune activation and tumor cell targeting in a single agent. Through integrated T cell signaling, its biologics directly targets tumor cells and provides potent, tissue-localized immune amplification at the tumor site to maximize tumor killing.	~ 10	1	Combination of bispecific antibodies and chimeric antigen receptor T cells for treatment (EP3000000/101110) - 2024 The invention provides both comprising a 2 nd antigen binding region that binds to a modified T cell, a 2 nd antigen binding region that binds to the tumor cell, and a 2 nd antigen binding region that binds to any other antigen. Bispecific antibody fusion molecules and methods of use thereof (EP3000000/101110) - 2024 The patent family describes fusions that bind to CD8 and CD28. The Ab are optionally fused with a CD28 peptide. Bispecific antibody fusion molecules and methods of use thereof (EP3000000/101110) - 2024 The patent family provides compositions and methods for the efficient production of a heteromultimeric antibodies, such as a bispecific antibodies.

* Companies acting as a front for other parties to conceal their identities (straw man)


Patent Portfolios Benchmarking: Beyond the Quantity

Who has the best patent portfolio?

SAMPLE

IP POSITION OF PATENT APPLICANTS

IP Leadership of Patent Assignees




Roche is a strong IP leader in the field of bispecific antibody for cancer therapy. With 670 granted patents and 500 pending patent applications, it has the largest portfolio and a wide geographical coverage. Although Roche is not a pioneer in the area, with a 1st patent family published in 2012, it takes the lead with an average of 13 patent families published by year. The company is known for its CrossMab technology to produce bispecific antibodies. "We produce our CrossMabs with the same biology used by nature and the same manufacturing process in mammalian cells established 50 years ago for monoclonal antibodies", says a researcher from Roche. "Our CrossMabs have no chemical linkers or connectors, that wouldn't be part of a natural antibody"

Amgen is also a strong IP leader with 675 granted patents and 670 pending patent applications. The 1st patent families owned by Amgen are filed by Microsoft and Intel.

IP POSITION OF PATENT APPLICANTS



Strength Index (2/2)



Bispecific antibody and cancer – Patent Landscape Analysis - Ref.: KMxxxx © 2025 All rights reserved | www.knowmade.com 53

IP POSITION OF PATENT APPLICANTS

Prior Art Blocking Potential



Patent portfolios with a high prior art IP blocking potential are relevant in evaluating the patentability of patent applications filed afterwards. Old patent families are more likely to receive a high number of citations from subsequent applications. Therefore, well-cited patent families are likely to be relevant prior art "blocking" the patenting activity of competitors (i.e., novelty and inventive step assessment).

Roche's patent portfolio has been identified as one of the most highly cited in the field of bispecific antibody and cancer treatment, receiving citations from various academics such as the University of Iowa, the University of Stanford, the University of California or the leading Maximilian University or various institutions such as Pinaris, Merck KGaA, Eli Lilly, AbbVie, AstraZenca, Samsung, Genentech or Pfizer.

Although BMS has only 11 patent families, its patent portfolio received a high number of citations, mainly for its 11 patent families, published between 1994 and 1998: EP060044, EP060045, EP060046, EP060047, EP060048, EP060049, EP060050, EP060051, EP060052, EP060053, EP060054. These patent families are cited by several key players in bispecific antibody area such as Roche, Genentech, Genmab, Genovex, Regeneron, Merck, Bristol-Myers Squibb and other BMS like regularity patent families in the field even if it is not the company's main activity.

Roche's patent portfolio is also very cited. The company holds the most highly-cited patent families in the area of bispecific antibody, with around 160 forward citations for 11 patent families filed by BMS (acquired in 2012) between 1994 and 2008: EP060044, EP060045, EP060046, EP060047, EP060048, EP060049, EP060050, EP060051, EP060052, EP060053, EP060054.

portfolio level. The identification of a "blocking patent" requires an in-depth specific test from the patent families. The IP blocking potential is an indicator of how an IP suit to circumvent in a technology. The IP blocking potential is not necessarily linked

Bispecific antibody and cancer – Patent Landscape Analysis - Ref.: KMxxxx © 2025 All rights reserved | www.knowmade.com 49

Patent Segmentation

What are the key IP players for each segments?


SAMPLE

Patent families were segmented into the following categories:

- **Tumor antigens:** ERBB family, BCMA, BRCA, mesothelin, PSMA, CEA, claudin, EPCAM, mucin, NKG2D, VEGF, CEACAM, MAGE, ROR1, c-Met and nectin.
- **Immune checkpoints:** PD1 / PDL1, CTLA-4, LAG-3, TIM-3, OX40, ICOS, B7-H3, TIGIT and BTLA.
- **T cell receptor: CD3.** Although alternative T cell targets, such as the $\alpha\beta$ TCR and T cell surface glycoprotein CD5, have been explored to redirect or engage T cells, bsTCEs targeting CD3 ϵ are the most advanced.

PATENT SEGMENTATION

BsAb bridging cancer cell: tumor antigens



Assignee (Ranked by strength score)	Paper country	Strength Index	Nb of patent families	% of patent families with 2 or more patents	Number of granted patents										Number of pending patents									
					All countries	USA	Europe	China	Japan	South Korea	India	Others	All countries	USA	Europe	China	Japan	South Korea	India	Others				
AbbVie	EP	2759	144	37%	171	37	33	37	26	9	10	6	3	107	21	39	19	24	19	26	8	10	7	
Amgen	US	2064	126	51%	106	38	42	28	13	15	13	5	12	308	15	46	22	19	13	12	20	3	3	
Novartis	US	1293	24	27%	349	106	16	13	12	4	1	3	1	77	6	12	4	4	7	2	3	2	2	
Roche	EP	1042	10	21%	179	82	10	6	5	3	3	3	1	49	6	5	2	2	2	1	1	1	1	
Merck	US	935	5	38%	147	49	5	6	2	2	2	1	24	4	1	1	1	1	1	1	1	1	1	
Novartis	UK	872	5	31%	73	3	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
Novartis	US	800	24	43%	597	91	15	8	8	1	2	2	1	11	54	24	27	29	26	7	11	15	15	
Novartis	EP	738	7	12%	110	53	9	8	5	2	1	1	1	38	5	9	5	4	1	1	3	4	4	
Novartis	US	713	14	48%	293	59	8	7	6	2	3	1	1	60	3	3	2	3	12	3	4	2	2	
Novartis	UK	654	7	38%	104	45	10	5	2	4	1	1	1	10	1	1	1	1	1	1	1	1	1	
Novartis	US	632	13	28%	259	113	19	13	4	5	6	5	6	5	13	2	4	4	5	6	4	2	2	
Novartis	EP	530	5	10%	103	14	2	3	1	1	1	1	1	9	1	1	1	1	1	1	1	1	1	
Novartis	US	467	26	55%	359	117	15	11	8	2	4	2	1	20	34	12	12	16	5	3	8	11	11	
Novartis	UK	463	20	38%	181	9	2	1	1	1	1	1	1	15	3	3	3	3	3	3	3	3	3	
Novartis	US	455	4	44%	32	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	

- ▶ Tumor antigen segment includes 1283 patent families (44% of total patent families).
- ▶ The strength score is led by Amgen which has published 164 patent families, (32% of the patent per strategy (more details in its IP profile). Its portfolio mainly described bsAb binding the EGFR family (such as M301, EPCAM or BCMA).
- ▶ Among patent families published in 2024, there is one patent family owned by Genentech but publishes FcAD binding domain and a CD3 binding domain. The chimera polypeptide has a mark segment positioned between the mark polypeptide and the bsAb domain. First, the mark can be used segment to describe polypeptide present in a tumor.



PATENT SEGMENTATION

Overview: Main assignees by technology

Assignee	Player country	Nb of patent families	Nb of patent publications	CD3	Tumor Antigens	Immune Checkpoints (IC)
Novartis	EP	174	2300	115	74	34
Amgen	US	104	2075	92	53	10
Novartis	US	71	1109	36	47	1
Novartis	EP	59	880	27	7	10
Novartis	US	50	479	26	10	18
Novartis	US	49	827	30	26	10
Novartis	EP	47	516	32	10	6
Novartis	US	43	841	20	12	14
Novartis	US	37	562	20	37	3
Novartis	EP	36	532	23	15	9
Novartis	EP/IP	36	510	26	7	2
Novartis	US	36	361	22	23	6
Novartis	EP	35	520	7	21	12
Novartis	US	33	476	19	24	3
Novartis	US	33	253	21	11	2
Novartis	KR	33	75	10	32	10
Novartis	CN	29	130	10	17	10
Novartis	US	29	611	4	14	3
Novartis	CN	27	43	16	8	3
Novartis	US	26	139	3	8	3
Novartis	CN	26	90	4	16	16
Novartis	EP	25	268	15	11	1

This table shows which segment the patent families filed by the main IP players belong to. Almost all players develop various bispecific antibodies. Regarding Roche and Amgen, the major players, they are focused on T cell engager (CD3 binding). One difference between them is that Amgen does not have patent family describing bsAb against immune checkpoints (IC). On the contrary, Amgen's patent portfolio has a lot of patent families as regards IC (39%). Most of the bsAb described in scientific and patent publications describe a bridge between CD3 on T cell and TN on cancer cell. However, Genentech's bispecific, an IC company founded in 2016, has opted for a different strategy by focusing on NK cells with bsAb bridging MHC1 on one side to on cancer cells. It is also interesting to note the specificity of Amgen, which is the only IP player focused on only one segment (tumor antigens).



PATENT SEGMENTATION


Overview: definition

One of the attractive features of bsAbs is their potential to display activity that is not present in any combination of parent antibodies. Indeed, bsAbs generate a new functionality depending on the physical linkage of the two specificities and cannot be obtained by combining separate antibodies with the same specificities. Because of this assumed novel activity such antibodies have been studied extensively. bsAbs that bridge cells as their ultimate mechanism of action represent the largest group, with T cell-mediated as the most common demonstration. The strength of bsAbs is their ability to connect novel functionalities that require two binding specificities to be connected in the same molecule. This can be exploited for innovative therapeutic concepts, for instance, to bridge two cell types (in-trans binding) or to engage two molecules on the membrane of one cell (in-cis binding). These concepts require simultaneous binding of the two specificities, while other relevant concepts are based on sequential binding of the two binding domains (Figure 10-10).

- **Bridging receptors (cis)** engages similarly bridges two Tumor Antigens (TA) on a cancer cancer cell or two Immune Checkpoints (IC) on a cancer T cell.

bsAbs can be divided into various categories based on their binding domains. For example, they can be divided into cis and trans binding. Cis binding involves two binding domains on the same molecule, while trans binding involves two binding domains on different molecules. The strength of bsAbs is their ability to connect novel functionalities that require two binding specificities to be connected in the same molecule. This can be exploited for innovative therapeutic concepts, for instance, to bridge two cell types (in-trans binding) or to engage two molecules on the membrane of one cell (in-cis binding). These concepts require simultaneous binding of the two specificities, while other relevant concepts are based on sequential binding of the two binding domains (Figure 10-10).

bsAbs can be divided into various categories based on their binding domains. For example, they can be divided into cis and trans binding. Cis binding involves two binding domains on the same molecule, while trans binding involves two binding domains on different molecules. The strength of bsAbs is their ability to connect novel functionalities that require two binding specificities to be connected in the same molecule. This can be exploited for innovative therapeutic concepts, for instance, to bridge two cell types (in-trans binding) or to engage two molecules on the membrane of one cell (in-cis binding). These concepts require simultaneous binding of the two specificities, while other relevant concepts are based on sequential binding of the two binding domains (Figure 10-10).



Excel file with all patents analyzed in the report

Useful patent database allows multi-criteria searches

SAMPLE

General information										Segmentation		
Family number	Patent number	Patent assignee	Title	Abstract	Earliest publication date	Citing patents (Forward citation)	PDF link	Biblio summary	CD3	Checkpoint inhibitors	Tumor antigens	
111634129	US20240425516 PK144225 PK144225 US20230340160 JP7175291 BR112014003769 CA2837975 IL268886 EP3892640 ES2857734 PL3321286 EP3321286 PK336320 EP4023670 AU2020267284 CN108546300 IN390990 VN0030615 CN113667020 CN107098975 EP3485301 CN106977606 KR10-2021-0013324 KR10-2210196	ROCHE	Bispecific t cell activating antigen binding molecules	(EP3892640) The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.	2013-02-28	US20200218522;US11370832 WO201506749 US20100322334;US8703132 WO201636918 US20140243505;US9079965 US20160075785;US9314776 US20160075785;US9314776 US20160075785;US11314776 US20160075785;US1142578 US20210077638;US11896682 WO201670816 EP3885344 JP2018520675 WO202402235 EP3216786 US20170355696;US10179784 US20160214978;US10	Open	Open	X			
111224666	EP4023670 AU2020267284 CN108546300 IN390990 VN0030615 CN113667020 CN107098975 EP3485301 CN106977606 KR10-2021-0013324 KR10-2210196	JANSSEN	Egfr and c-met-fibronectin type iii domain binding molecules	(EP4023670) Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.	2014-05-30	US20160075785;US11314776 US20160075785;US1142578 US20210077638;US11896682 WO201670816 EP3885344 JP2018520675 WO202402235 EP3216786 US20170355696;US10179784 US20160214978;US10	Open	Open		X		
111136189	WO2024173607 WO2024173607	EVOLVEIMMUNE THERAPEUTICS	Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment	(WO2024173607) The present disclosure provides bispecific antibodies comprising a first antigen binding region that binds to a modified T cell or CAR domain expressed on a modified T cell, a second antigen binding region that binds to the tumor cell, and an at least third antigen binding region that binds to any other antigen (e.g., a biological molecule, e.g., a cell surface antigen, e.g., a disease associated antigen). Also included are methods of use thereof, including T-cell re-targeting, and treating cancer in a subject in need thereof.	2024-08-22		Open	Open	X		X	
111136042	WO2024173376 WO2024173376	LAVA THERAPEUTICS	Combination therapy comprising multispecific gamma delta tcr antibodies	(WO2024173376) The present disclosure relates to a method for the treatment of cancer comprising administration to a subject in need thereof, of a multispecific antibody comprising a first antigen-binding region capable of binding a human cancer antigen and a second antigen-binding region capable of binding a human Vγ9Vδ2 T cell receptor, in combination with a common gamma chain cytokine and/or an immune checkpoint inhibitor.	2024-08-22		Open	Open			X	
111133254	CN118823655	CENTRYMED PHARMACEUTICAL	Egfr and lan3 dual targeted bispecific	(WO2024168588) Disclosed herein are bispecific antibodies against EGFR and LAG3, nucleic acids comprising the antibodies, vectors comprising the nucleic acids, and host cell comprising the nucleic acids or the	2024-08-22		Open	Open		X	X	

Patent information

Segmentation

Online database with all patents analyzed in the report

Useful online patent database with updated legal status

SAMPLE

Bispecific t cell activating antigen binding molecules

Abstract

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Images (99)



Classifications

Claims

(EP3892640)

1. A T cell activating bispecific antigen binding molecule comprising
 - (i) a first antigen binding moiety, which is a Fab molecule capable of specific binding to an activating T cell antigen,
 - (ii) a second and a third antigen binding moiety, which are each a Fab molecule capable of specific binding to a target cell antigen, and
 - (iii) an Fc domain composed of a first and a second subunit capable of stable association; wherein (a) the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety, and the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain, or (b) the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding moiety, and the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain; and wherein the T cell activating bispecific antigen binding molecule comprises not more than one antigen binding moiety capable of specific binding to an activating T cell antigen.
2. The T cell activating bispecific antigen binding molecule of claim 1, wherein the activating T cell antigen is CD3.
3. The T cell activating bispecific antigen binding molecule of claim 1 or 2, wherein the first and the

EP3892640 A1

GRANTED ALIVE

Earliest priority date : 2011-08-23

Download PDF

Assignee ROCHE GLYCART

Inventor AST OLIVER · BRUENKER PETER · FAUTI TANJA · FREIMOSER-GRUNDSCHOBER ANNE · JAEGER CHRISTIANE · KLEIN CHRISTIAN · MOESSNER EKKEHARD · UMAÑA PABLO

Protected countries
DE · NO · RS · BE · FI · TW · PT · BG · JP · DK · LT · HR · FR · UA · HU · BR · SE · MA · SG · SI · SK · GB · IE · GC · CA · IL · CH · KR · ZA · CN · EP · GR · IT · MX · MY · ES · AT · AU · CZ · VN · PK · PL · RO · NL · TR · IN · PE · CL · CO · US · CR



Patent family overview

Applications · Publications · Legal status

Applications	Publication number	Application date	Legal status
PK	PK144225	2012	Granted
WO	WO2013/026833	2012	Lapsed
CA	CA2837975	2012	Granted
AU	AU2012298537	2012	Granted
IL	IL229765	2012	Granted
KR	KR10-1963923	2012	Granted
CN	CN103748114	2012	Granted
MX	MX352101	2012	Granted
EP	EP2748201	2012	Granted
PT	PT2748201	2012	Granted
DK	DK2748201	2012	Granted
LT	LT2748201	2012	Granted
ES	ES2659764	2012	Granted

< > 1/99

Highlight



SAMPLE

ORDER FORM

Bispecific Antibody and Cancer

Patent Landscape Analysis – January 2025

Ref.:KM25001



SHIP TO

Name (Mr/Ms/Dr/Pr):

Job Title:

Company:

Address:

City:

State:

Postcode/Zip:

Country:

VAT ID Number for EU members:

Tel:

Email:

Date:

PAYMENT METHODS

Check

To pay your invoice using a check, please mail your check to the following address:

KnowMade S.A.R.L.
2405 route des Dolines
06902 Valbonne Sophia Antipolis
FRANCE

Money Transfer

To pay your invoice using a bank money wire transfer please contact your bank to complete this process. Here is the information that you will need to submit the payment:

Payee: KnowMade S.A.R.L.
Bank: Banque Populaire Méditerranée, CAP 3000 Quartier du lac, 06700 St Laurent du Var, France
IBAN: FR76 1460 7003 6360 6214 5695 139
BIC/SWIFT: CCBPFRPPMAR

Paypal

In order to pay your invoice via PAYPAL, you must first register at www.paypal.com. Then you can send money to the KnowMade S.A.R.L. by entering our E-mail address contact@knowmade.fr as the recipient and entering the invoice amount.

RETURN ORDER BY

E-mail: contact@knowmade.fr

Mail: KnowMade S.A.R.L., 2405 route des Dolines, 06902 Valbonne Sophia Antipolis, FRANCE

PRODUCT ORDER

€4,990 – Multi user license*

For price in dollars, please use the day's exchange rate. For French customer, add 20% for VAT.

All reports are delivered electronically in PDF format at payment reception.

**The report can be shared with the employees of the Company purchasing the report. Subsidiaries and joint-ventures are excluded. Please be aware that the report is watermarked on each page, with the name of the recipient and the organization (the name mentioned on the PO). This watermark also reaffirms that report sharing is not allowed.*

I hereby accept Knowmade's Terms and Conditions of Sale

Signature:

Terms and Conditions of Sales

SAMPLE

DEFINITIONS

“Acceptance”: Action by which the Buyer accepts the terms and conditions of sale in their entirety. It is done by signing the purchase order which mentions “I hereby accept Knowmade’s Terms and Conditions of Sale”.

“Buyer”: Any business user (i.e. any person acting in the course of its business activities, for its business needs) entering into the following general conditions to the exclusion of consumers acting in their personal interests.

“Contracting Parties” or “Parties”: The Seller on the one hand and the Buyer on the other hand.

“Intellectual Property Rights” (“IPR”) means any rights held by the Seller in its Products, including any patents, trademarks, registered models, designs, copyrights, inventions, commercial secrets and know-how, technical information, company or trading names and any other intellectual property rights or similar in any part of the world, notwithstanding the fact that they have been registered or not and including any pending registration of one of the above mentioned rights.

“License”: For the reports and databases, 2 different licenses are proposed. The buyer has to choose one license:

1. Single user license: a single individual at the company can use the report.

2. Multi user license: The report can be shared with the employees of the Company purchasing the report. Subsidiaries and joint-ventures are excluded.

“Products”: Reports are established in PowerPoint and delivered on a PDF format and the database may include Excel files.

“Seller”: Based in Sophia Antipolis (France headquarters), Knowmade is a technology intelligence company specialized in the research and analysis of scientific and technical information. We provide patent landscapes and scientific state of the art with high added value to businesses and research laboratories. Our intelligence digests play a key role to define your innovation and development strategy.

1. SCOPE

1.1 The Contracting Parties undertake to observe the following general conditions when agreed by the Buyer and the Seller. ANY ADDITIONAL, DIFFERENT, OR CONFLICTING TERMS AND CONDITIONS IN ANY OTHER DOCUMENTS ISSUED BY THE BUYER AT ANY TIME ARE HEREBY OBJECTED TO BY THE SELLER, SHALL BE WHOLLY INAPPLICABLE TO ANY SALE MADE HEREUNDER AND SHALL NOT BE BINDING IN ANY WAY ON THE SELLER.

1.2 This agreement becomes valid and enforceable between the Contracting Parties after clear and non-ambiguous consent by any duly authorized person representing the Buyer. For these purposes, the Buyer accepts these conditions of sales when signing the purchase order which mentions “I hereby accept Knowmade’s Terms and Conditions of Sale”. This results in acceptance by the Buyer.

1.3 Orders are deemed to be accepted only upon written acceptance and confirmation by the Seller, within [7 days] from the date of order, to be sent either by email or to the Buyer’s address. In the absence of any confirmation in writing, orders shall be deemed to have been accepted.

2. MAILING OF THE PRODUCTS

2.1 Products are sent by email to the Buyer:

- within [1] month from the order for Products already released; or

- within a reasonable time for Products ordered prior to their effective release. In this case, the Seller shall use its best endeavours to inform the Buyer of an indicative release date and the evolution of the work in progress.

2.2 Some weeks prior to the release date the Seller can propose a pre-release discount to the Buyer.

The Seller shall by no means be responsible for any delay in respect of article 2.2 above, and including in cases where a new event or access to new contradictory information would require for the analyst extra time to compute or compare the data in order to enable the Seller to deliver a high quality Products.

2.3 The mailing of the Product will occur only upon payment by the Buyer, in accordance with the conditions contained in article 3.

2.4 The mailing is operated through electronic means either by email via the sales department. If the Product’s electronic delivery format is defective, the Seller undertakes to replace it at no charge to the Buyer provided that it is informed of the defective formatting within 90 days from the date of the original download or receipt of the Product.

2.5 The person receiving the Products on behalf of the Buyer shall immediately verify the quality of the Products and their conformity to the order. Any claim for apparent defects or for non-conformity shall be

sent in writing to the Seller within 8 days of receipt of the Products. For this purpose, the Buyer agrees to produce sufficient evidence of such defects.

2.6 No return of Products shall be accepted without prior information to the Seller, even in case of delayed delivery. Any Product returned to the Seller without providing prior information to the Seller as required under article 2.5 shall remain at the Buyer’s risk.

3. PRICE, INVOICING AND PAYMENT

3.1 Prices are given in the orders corresponding to each Product sold on a unit basis or corresponding to annual subscriptions. They are expressed to be inclusive of all taxes. The prices may be reevaluated from time to time. The effective price is deemed to be the one applicable at the time of the order.

3.2 Payments due by the Buyer shall be sent by cheque payable to Knowmade, PayPal or by electronic transfer to the following account:

Banque Populaire Méditerranée, CAP 3000 Quartier du lac, 06700 St Laurent du Var, France

BIC or SWIFT code: CCBPFRPPMAR

IBAN: : FR76 1460 7003 6360 6214 5695 139

To ensure the payments, the Seller reserves the right to request down payments from the Buyer. In this case, the need of down payments will be mentioned on the order.

3.3 Payment is due by the Buyer to the Seller within 30 days from invoice date, except in the case of a particular written agreement. If the Buyer fails to pay within this time and fails to contact the Seller, the latter shall be entitled to invoice interest in arrears based on the annual rate Refi of the «BCE» + 7 points, in accordance with article L. 441-6 of the French Commercial Code. Our publications (report, database, tool...) are delivered only after reception of the payment.

3.4 In the event of termination of the contract, or of misconduct, during the contract, the Seller will have the right to invoice at the stage in progress, and to take legal action for damages.

4. LIABILITIES

4.1 The Buyer or any other individual or legal person acting on its behalf, being a business user buying the Products for its business activities, shall be solely responsible for choosing the Products and for the use and interpretations he makes of the documents it purchases, of the results he obtains, and of the advice and acts it deduces thereof.

4.2 The Seller shall only be liable for (i) direct and (ii) foreseeable pecuniary loss, caused by the Products or arising from a material breach of this agreement

4.3 In no event shall the Seller be liable for:

a) damages of any kind, including without limitation, incidental or consequential damages (including, but not limited to, damages for loss of profits, business interruption and loss of programs or information) arising out of the use of or inability to use the Seller’s website or the Products, or any information provided on the website, or in the Products;

b) any claim attributable to errors, omissions or other inaccuracies in the Product or interpretations thereof.

4.4 All the information contained in the Products has been obtained from sources believed to be reliable. The Seller does not warrant the accuracy, completeness adequacy or reliability of such information, which cannot be guaranteed to be free from errors.

4.5 All the Products that the Seller sells may, upon prior notice to the Buyer from time to time be modified by or substituted with similar Products meeting the needs of the Buyer. This modification shall not lead to the liability of the Seller, provided that the Seller ensures the substituted Product is similar to the Product initially ordered.

4.6 In the case where, after inspection, it is acknowledged that the Products contain defects, the Seller undertakes to replace the defective products as far as the supplies allow and without indemnities or compensation of any kind for labor costs, delays, loss caused or any other reason. The replacement is guaranteed for a maximum of two months starting from the delivery date. Any replacement is excluded for any event as set out in article 5 below.

4.7 The deadlines that the Seller is asked to state for the mailing of the Products are given for information only and are not guaranteed. If such deadlines are not met, it shall not lead to any damages or cancellation of the orders, except for non-acceptable delays exceeding [4] months from the stated deadline, without information from the Seller. In such case only, the Buyer shall be entitled to ask for a reimbursement of its first down payment to the exclusion of any further damages.

4.8 The Seller does not make any warranties, express or implied, including, without limitation, those of

saleability and fitness for a particular purpose, with respect to the Products. Although the Seller shall take reasonable steps to screen Products for infection of viruses, worms, Trojan horses or other codes containing contaminating or destructive properties before making the Products available, the Seller cannot guarantee that any Product will be free from infection.

5. FORCE MAJEURE

The Seller shall not be liable for any delay in performance directly or indirectly caused by or resulting from acts of nature, fire, flood, accident, riot, war, government intervention, embargoes, strikes, labor difficulties, equipment failure, late deliveries by suppliers or other difficulties which are beyond the control, and not the fault of the Seller.

6. PROTECTION OF THE SELLER’S intellectual property

6.1 All intellectual property rights attached to the Products are and remain the property of the Seller and are protected under French and international copyright law and conventions.

6.2 The Buyer agreed not to disclose, copy, reproduce, redistribute, resell or publish the Product, or any part of it to any other party other than employees of its company. The Buyer shall have the right to use the Products solely for its own internal information purposes. In particular, the Buyer shall therefore not use the Product for purposes such as:

- Information storage and retrieval systems;

- Recordings and re-transmittals over any network (including any local area network);

- use in any timesharing, service bureau, bulletin board or similar arrangement or public display;

- Posting any Product to any other online service (including bulletin boards or the Internet);

- Licensing, leasing, selling, offering for sale or assigning the Product.

6.3 The Buyer shall be solely responsible towards the Seller of all infringements of this obligation, whether this infringement comes from its employees or any person to whom the Buyer has sent the Products and shall personally take care of any related proceedings, and the Buyer shall bear related financial consequences in their entirety.

6.4 The Buyer shall define within its company point of contact for the needs of the contract. This person will be the recipient of each new report in PDF format. This person shall also be responsible for respect of the copyrights and will guaranty that the Products are not disseminated out of the company.

7. TERMINATION

7.1 If the Buyer cancels the order in whole or in part or postpones the date of mailing, the Buyer shall indemnify the Seller for the entire costs that have been incurred as at the date of notification by the Buyer of such delay or cancellation. This may also apply for any other direct or indirect consequential loss that may be borne by the Seller, following this decision.

7.2 In the event of breach by one Party under these conditions or the order, the non-breaching Party may send a notification to the other by recorded delivery letter upon which, after a period of thirty (30) days without solving the problem, the non-breaching Party shall be entitled to terminate all the pending orders, without being liable for any compensation.

8. MISCELLANEOUS

All the provisions of these Terms and Conditions are for the benefit of the Seller itself, but also for its licensors, employees and agents. Each of them is entitled to assert and enforce those provisions against the Buyer.

Any notices under these Terms and Conditions shall be given in writing. They shall be effective upon receipt by the other Party.

The Seller may, from time to time, update these Terms and Conditions and the Buyer, is deemed to have accepted the latest version of these terms and conditions, provided they have been communicated to him in due time.

9. GOVERNING LAW AND JURISDICTION

9.1 Any dispute arising out or linked to these Terms and Conditions or to any contract (orders) entered into in application of these Terms and Conditions shall be settled by the French Commercial Courts of Grasse, which shall have exclusive jurisdiction upon such issues.

9.2 French law shall govern the relation between the Buyer and the Seller, in accordance with these Terms and Conditions.

SAMPLE



KNOWMADE

Company presentation

KNOWMADE PURPOSE

SAMPLE

Turning **patent information** and **scientific literature** into actionable insights, providing high value-added reports for **decision-makers** working in **R&D, Intellectual Property, Innovation Strategy, and Marketing**

Competitive landscape | Technology trends | Opportunities / Risks | R&D and IP strategy



CUSTOM SERVICES

(Tailor-made analysis)

To meet your needs and budget/lead time constraints

- Specific and dedicated report.
- Prior-art search, literature review, patent landscape, freedom-to-operate, patent valuation, IP due diligence, technology scouting, monitoring service, etc.

Format

- PDF file with analyses.
- Excel file with data.
- Access to the analyst.

REPORTS

(multi-client product)

To understand the competitive landscape and explore the emerging ecosystems and new technologies

- Stand alone report
- Patent landscape.
- Overview on IP dynamics, trends and players.
- Competitor, technology and strategy analysis.
- Benchmark of patent portfolios.
- Key IP players & key patents.

Format

- PDF file with analyses.
- Excel file with patent data.

MONITORS

(multi-client product)

To track the latest R&D developments and IP activities, and to be sensitive to weak signals

- Annual subscription
- Patent monitoring service.
- Quarterly updated patent data and technology trends.
- Current R&D and IP activities.
- Early detect weak signals, opportunities and risks.
- Open discussion with analyst.

Format

- PDF file with analyses.
- Excel file with patent data.
- Direct access to the analyst.

INSIGHTS

(free article & webinar)

To get unique information about industry and technology

- Analyst point of view about industry news (product release, M&A, start-up, fund-raising, etc.) from a patent perspective.

Format

- Knowmade website

MAIN FIELDS OF EXPERTISE

SEMICONDUCTORS

- Materials & Substrates
- Power electronics
- RF & Wireless datacom
- MEMS, Sensing & Imaging
- Photonics, Lighting & Display
- Memory
- Packaging

ENERGY

- Batteries
- Fuel-cells
- Solar PV
- Power management



HEALTHCARE

- New therapeutic tools
- Medical diagnostics
- Medical devices and imaging
- Drug discovery and delivery

AGRI-FOOD

- Food processing & formulation
- Vegan food
- Next-gen packaging
- Microbiology

SAMPLE



www.knowmade.com

contact@knowmade.fr

KnowMade S.A.R.L., 2405 route des Dolines, 06902 Sophia Antipolis, France